High risk features of malignant polyps David F. Schaeffer, MD, FRCPC Associate Professor, Department of Pathology and Laboratory Medicine, UBC Head, Department of Pathology, Vancouver Coastal Health Pathology Lead, ECAC John Cancer Screening Program



DISCLOSURES



Relationships with commercial interests:

- Consulting Fees: Alimentiv, Pfizer, Merck and Diaceutics
- Scientific Advisory Board: Satisfai Health Inc.

Material presented is unrelated to financial relationship with commercial entities.

PATHOLOGY REPORT OF MALIGNANT POLYPS

1. Presence/absence of poorly differentiated carcinoma (any amount)
2. Presence/absence of angiolymphatic invasion
3. Presence/absence of high-grade tumor budding
4. Distance of invasive component to margin/completeness of excision
5. Depth/Width of invasion





























































